What you should know before using Xeljanz XR
Before you buy Xeljanz XR online, the following factors should be considered:
Before treatment begins, patients need to be tested for latent tuberculosis. If the test is positive, treatment for tuberculosis should begin before starting Xeljanz XR. All patients need to be monitored for symptoms and signs of an infection during and after treatment with Xeljanz XR, even if the tuberculosis test is negative.
This medication is not recommended for patients with severe liver problems.
Rheumatoid arthritis patients who also demonstrate at least one cardiovascular risk factor generally have a higher rate of all-cause mortality and thrombosis when taking XELJANZ XR.
The use of XELJANZ XR should be avoided during a serious active infection, including localized infections.
Patients who are at risk of pulmonary, deep venous, and arterial thrombosis should avoid taking XELJANZ XR as this complication can become fatal if it occurs during treatment. Patients with symptoms of thrombosis should be promptly evaluated and treatment should be discontinued.
Use this medication with caution in patients who may be at an increased risk for gastrointestinal perforations.
Regular laboratory monitoring is recommended due to potential changes hemoglobin, lymphocytes, lipids, neutrophils, and liver enzymes.
The use of this drug should be avoided in patients who have had live vaccines (immunizations).
This medication is not recommended for nursing mothers. Information pertaining to the effects of Xeljanz XR in pregnant women is limited, but animal models indicate that the risk for potential harm to an unborn baby cannot be ruled out.